Company: LIMN
Filing Date: 2025-01-27
Form Type: POS AM
Source: 0001104659-25-006325
Chunk: 202

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-27
Form: POS AM
Chunk 202
---
 balance sheet as of September 30, 2024 and unaudited pro forma combined statement of operations for the nine months ended September 30, 2024 has been derived from and should be read in conjunction with the following:

•

the historical unaudited financial statements of Iris as of September 30, 2024 and for the nine months ended September 30, 2024 and the related notes, which are included in Iris’s Quarterly Report on Form 10-Q filed with the SEC on November 27, 2024 (the “Iris September 2024 10-Q”), which are included elsewhere in this proxy statement/prospectus; and

•

the historical unaudited financial statements of Liminatus as of September 30, 2024 and for the nine months ended September 30, 2024 and the related notes, which are included elsewhere in this proxy statement/ prospectus.

The unaudited pro forma combined statement of operations for the year ended December 31, 2023 has been derived from and should be read in conjunction with the following:

•

the historical audited financial statements of Iris as of and for the year ended December 31, 2023 and the related notes, which are included in Iris’s Annual Report on Form 10-K filed with the SEC on April 17, 2024 (the “Iris 2023 10-K”), which is included elsewhere in this proxy statement/prospectus; and

•

the historical audited financial statements of Liminatus as of and for the year ended December 31, 2023 and the related notes, which are included elsewhere in this proxy statement/prospectus.

The unaudited pro forma combined financial information should also be read together with the sections of the Iris September 2024 10-Q, Iris 2023 10-K, the financial statements of Liminatus as of and for the nine months ended September 30, 2024, the financial statements of Liminatus as of and for the year ended December 31, 2023 and the section of this proxy statement/prospectus entitled “Iris’s Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and “Liminatus’s Management’s Discussion and Analysis of Financial Condition and Results of Operations,” as well as other financial information included elsewhere in this proxy statement/prospectus.

Business Combination Agreement

On November 30, 2022, Iris entered into a Business Combination Agreement (as it may be amended